IMPROVING PANCREATIC ISLET SURVIVAL IN CELL ENCAPSULATION DEVICES FOR THE TREATMENT OF TYPE 1 DIABETES
Type 1 Diabetes (T1D) is an autoimmune disease that arises from the selective destruction of the pancreatic islets, the cell clusters responsible for regulating glucose levels through the careful secretion of insulin and glucagon. While T1D can be effectively treated using exogenous sources of insulin, chronic instances of hyperglycemia eventually result in serious complications including neuropathy, kidney damage, and glaucoma. Many T1D patients also report high levels of anxiety stemming from the vigilant self-monitoring of blood glucose and injections of insulin. As an alternative treatment, researchers have been investigating the use of pancreatic islet transplants to create a self-regulating source of pancreatic endocrine hormones. In order to minimize graft loss due to immune rejection without the need for immunosuppressive drugs, the islets can be encapsulated in semi-permeable membranes. These so called cell encapsulation devices have shown promise in animal models but have so far failed to translate to the clinic in any significant manner due to graft failure caused by foreign body fibrosis, insufficient nutrients, or small diffuse molecules penetrating the protective material. This dissertation utilized separate strategies to address each of these limitations with the aim of improving pancreatic islet survival and function in cell encapsulation devices. Foreign body fibrosis remains the most obvious cause of many biomedical implant failures. The thick collagen deposits on the surface of devices effectively seals them off from the body, making it impossible for therapeutic proteins such as insulin to diffuse out and for nutrients like glucose and oxygen from diffusing into the device. The first study of this dissertation aimed to minimize the formation of foreign body fibrosis and improve the mass transfer capabilities by combining the benefits of micro and macroencapsulation devices. Utilizing a unique internal crosslinking system, we were able to create a robust, retrievable cell encapsulation device that we named Thread-Reinforced Alginate Fiber for Islets enCapsulation (TRAFFIC). By varying the amount of crosslinking divalent ions present in the thread along with time in the gel precursor we were able to tightly control the thread’s diameter. Using mouse and canine xenografts, we confirmed that larger diameter TRAFFIC devices consistently minimized fibrosis and could support the survival of rat islets in immunocompetent mice and dogs for 3 months and 1 month respectively and human islets in immunodeficient mice for 4 months. The vast majority of cell encapsulation devices are static in nature, meaning that the only means of nutrient and signaling exchange is through passive diffusion through the polymer membrane of the device. This presents a significant challenge as islets are one of the most energy demanding structures in the body and a large cell mass is needed to correct diabetes in patients resulting in large devices that often have poor surface to volume ratios. The second study presented in this dissertation aims to increase the delivery of vital nutrients to the implanted islets using preformed vascular meshes. Harnessing the natural contractile tendency of endothelial cells, we utilized a system of pillars to create robust and scalable self-assembled vasculature, a process we named Anchored Self-Assembly (ASA). The vessel networks created with human umbilical vein endothelial cells (HUVECs) using ASA were mechanically strong, easily transferred to the surface of a variety of devices, produced stable mature vessels with hollow lumens, and when implanted in vivo quickly became patent and anastamosed to the native vasculature. This improved access to blood flow allowed for rat islets implanted in the subcutaneous space of STZ diabetic immuno-deficient mice to remain functional for significantly longer than unsupported cells. The third and final study presented in this dissertation aims to understand the mechanism behind the loss of function of implanted beta cells. Despite technological advances in both fibrosis prevention and nutrient delivery, no cell encapsulation device for the treatment of T1D has shown efficacy in clinical trials. The implanted cell mass often show decreased insulin secretion and glucose responsivity. Drawing from research showing increased proliferation and inflammatory signaling of islet resident macrophages in Type 2 Diabetes (T2D), we examined their role in altering islet endocrine cell behavior. By selective depletion of the islet resident macrophages using clodronate liposomes, we demonstrated a protective effect against the disruptive effects of IFN_ and IL-1_ exposure. When isolated rat islets depleted of resident macrophages were encapsulated in alginate microcapsules and implanted in STZ diabetic mice, they produced a more stable therapeutic effect while requiring a smaller cell mass. The eventual translation of a cell encapsulation device from bench to bedside requires a multi-pronged approach to address the different limitations currently facing the field. Through varied strategies addressing foreign body fibrosis, nutrient deficiency, and islet functionality, the three studies described in this dissertation aims to increase the longevity of encapsulated pancreatic islets in the hopes of creating a more viable therapy option for T1D patients.